tremelimumab,oxaliplatin,camrelizumab,sorafenib,durvalumab,daratumumab,bevacizumab,pembrolizumab,atezolizumab,lenvatinib
bayer,pfizer,jiangsu hengrui pharmaceuticals,astrazeneca,roche,merck,eisai
['keynote-240', 'key,note,52', 'kn-394', 'check,mate,017', 'keynote,54', 'ca,022,i', 'himalaya', 'check,mate,003', 'imbrave150', 'lenva', 'ca,209,358', 'ca,022,1', 'key,note,45', 'bevacizumab', 'key,note,62', 'key,note,42', 'key,note,394', 'keynote-22', 'bevacizumab bio', 'sorafenib', 'surf', 'atezo', 'ca,209,449', 'ca,022,001', 'keynote-224', 'check,mate,025', 'tislelizumab', 'scot ', 'kn-240', 'keynote,91', 'pembro', 'kn-24', 'key,note,48', 'sintilimab', 'oxaliplatin', 'biomarker', 'ser,155,001', 'key,note,d15', 'tremelimumab', 'dance', 'leap-002', 'key,note,24', 'durva', 'check,mate,358', 'lung', 'hcc', 'aster,70', 'kn-22', 'camrelizumab', 'key,note,57', 'kn-224', 'boehringer', 'kura ', 'regeneron', 'astrazeneca', 'novartis', ' lilly', 'pfizer', 'astellas', 'marker ', 'msd', 'tessa', 'ab science', 'genentech', ' arcus ', 'roche,(-broche),(-rocheter)', 'merck']
 kn-394: pembro in 2nd line #hcc pos. phs-iii kn-224: mos 13.2 mo kn-240 &amp; 394: mos 14,2 mo leap-002: mos 21,2 mo (p+lenva) the next act in the drama -&gt; 4 studies with os data, but no approval... #livertwitter 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision medicine